Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07148908Not ApplicableRecruiting

Animal and Microbial-based Dietary Protein Efficiency in Adults

Role: lead

NCT05554653Not ApplicableUnknown

Influence of Leucine Enriched Amino Acids on Myofibrillar and Collagen Protein Synthesis

Role: lead

NCT03163043Not ApplicableCompleted

Protein Requirements for Active Children

Role: lead

NCT01180062Phase 1Terminated

Safety Study of Latanoprost Slow Release Insert

Role: lead

All 4 trials loaded